Introduction {#cesec10}
============

Observational studies show a strong, positive, and dose-related association between serum concentrations of homocysteine and the risk of stroke, which is independent of other vascular risk factors and biologically plausible.[@bib1; @bib2] Homocysteine can be lowered by a mean of 25% (95% CI 23--28) with folic acid supplementation.[@bib3] A meta-analysis of eight randomised, placebo-controlled trials of folic acid supplementation in 37 485 patients[@bib4] showed that, despite yielding an average 25% reduction in homocysteine, folic acid had no significant effect on the rate of first stroke (rate ratio 0·96, 95% CI 0·87--1·06) over a median follow-up of 5 years. However, the role of homocysteine-lowering in stroke prevention might be complex.[@bib5] A meta-analysis of 237 genetic epidemiological studies,[@bib6] in which homocysteine and the presence of the methylene tetrahydrofolate reductase C677T polymorphism in 60 000 individuals were correlated with 20 885 subsequent stroke events, suggested that established or increasing dietary folate intake in the countries where the trials were undertaken might have modified the effect of lowering homocysteine on risk of stroke.[@bib6]

Antiplatelet therapy might also modify the effect of lowering homocysteine on the risk of stroke and ischaemic heart disease events.[@bib7; @bib8; @bib9] An exploratory analysis of trials of lowering homocysteine[@bib7] suggested an interaction between antiplatelet therapy and the effect of lowering homocysteine on risk of ischaemic heart disease events: in the five trials with the lowest prevalence of antiplatelet therapy (mean 60%, usually aspirin), the relative risk was 0·93 (95% CI 0·84--1·05) and in the five trials with the highest prevalence (mean 91%) the relative risk was 1·09 (1·00--1·19), p for interaction=0·037. In another analysis of trials of the effects of lowering homocysteine on the risk of stroke events,[@bib8] the effect was greater in the four trials that enrolled patients with renal disease and oesophageal dysplasia (who were not likely to be taking antiplatelet therapy) compared with the trials that enrolled patients with previous vascular disease. The Heart Outcomes Prevention Evaluation 2 (HOPE 2) trial[@bib9] subsequently reported a non-significant trend towards a greater effect of folic acid-based vitamin B supplementation, compared with placebo, in reducing stroke in patients with known cardiovascular disease who were not taking antiplatelet therapy at enrolment compared with patients who were (p for interaction=0·25). The biological plausibility of these findings is supported by the recognised potential for antiplatelet therapy to modify any antithrombotic or other antiatherogenic effects of lowering homocysteine.[@bib10; @bib11; @bib12; @bib13]

These analyses prompted us to undertake a post-hoc subanalysis of the vitamins to prevent stroke (VITATOPS) trial. We aimed to explore the hypothesis that there is an interaction between antiplatelet therapy and the effect of folic acid-based vitamin B supplementation on major vascular events in the VITATOPS trial population of patients with previous stroke or transient ischaemic attack.[@bib14]

Methods {#cesec20}
=======

Participants {#cesec30}
------------

The methods and primary results of the VITATOPS trial have been reported.[@bib14] Briefly, the VITATOPS trial was a randomised, double-blind, parallel, placebo-controlled trial in which 8164 patients were recruited from 123 centres in 20 countries of four continents, and randomly assigned to take one tablet daily of placebo or B vitamins (2 mg folic acid, 25 mg vitamin B~6~, 500 μg vitamin B~12~). Patients were eligible for inclusion if they had a stroke (ischaemic or haemorrhagic) or transient ischaemic attack (eye or brain) within the past 7 months.

Patients were excluded if they were taking folic acid, vitamin B~6~, vitamin B~12~, or a folate antagonist (eg, methotrexate), if they were pregnant or were women of childbearing potential, or if they had a restricted life expectancy (eg, because of ill health).

At enrolment, participants were asked if they were taking antiplatelet drugs (eg, aspirin, clopidogrel, dipyridamole). The trial received ethical approval from national (India, New Zealand, and the UK) and local research ethics committees and all patients provided written informed consent before enrolment.

Procedures {#cesec40}
----------

Patients were randomly assigned (1:1) to receive either B vitamins or matching placebo by means of a central 24 h telephone service or an interactive website in which random permuted blocks were stratified by hospital. Treatment groups were masked from patients and investigators. Randomisation was not stratified in accordance with the presence or absence of antiplatelet therapy. The primary outcome was the composite of any stroke, myocardial infarction, or death from vascular causes.

Statistical analysis {#cesec50}
--------------------

We tabulated baseline characteristics and laboratory data in accordance with the presence or absence of antiplatelet therapy at baseline and in accordance with the assigned treatment groups, and expressed them as proportions for categorical variables and means for continuous variables. We compared categorical variables in each group with the χ^2^ test, and continuous variables with the *t* test. We calculated event rates as the number of events during the follow-up period divided by the total number of patients that entered randomisation.

We constructed Kaplan-Meier curves to show the cumulative effects of B vitamins compared with placebo on the primary outcome in participants who were and were not taking antiplatelet therapy at baseline.

We assessed the interaction between antiplatelet therapy and the effects of treatment with B vitamins on the primary outcome by means of Cox proportional hazards regression before and after adjusting for imbalances in important baseline prognostic factors in participants who were and were not taking antiplatelet drugs at baseline, and in participants assigned B vitamins or placebo. We also assessed the consistency of the interaction effect in different subgroups of patients, and in different secondary outcome events including ischaemic stroke, haemorrhagic stroke, myocardial infarction, and death from vascular causes.

We adjusted for certain variables in our models: age, sex, ethnic origin, pathological and causal subtypes of stroke and transient ischaemic attack, stroke severity as measured by the Oxford handicap score, smoking, treated and untreated hypercholesterolaemia, and history of stroke, myocardial infarction, ischaemic heart disease, peripheral arterial disease, atrial fibrillation, and diabetes.

We compared the mean serum concentrations of homocysteine and vitamin B~12~ and mean red-cell concentration of folate, which were measured at both baseline and follow-up in the same individual, with a paired *t* test. We calculated the difference between baseline and follow-up measures, and tested the interaction effect between antiplatelet use at baseline and treatment allocation with a linear regression model.

We used two-sided significance tests throughout and we deemed a two-sided p value of less than 0·05 to be significant. The VITATOPS trial is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov), number [NCT00097669](ctgov:NCT00097669), and Current Controlled Trials, number [ISRCTN74743444](ctgov:ISRCTN74743444).

Role of the funding source {#cesec60}
--------------------------

The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, the writing of the report, or in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#cesec70}
=======

At baseline, 6609 patients (81%) were in receipt of antiplatelet therapy, 1463 (18%) were not, and in 92 (1%) antiplatelet therapy status was not known. The composite primary outcome of stroke, myocardial infarction, or death from vascular causes was recorded in 616 patients (15%) assigned to receive B vitamins and 678 (17%) assigned to receive placebo (risk ratio 0·91, 95% CI 0·82 to 1·00, p=0·05; absolute risk reduction 1·56%, 95% CI −0·01 to 3·16).[@bib14]

Compared with patients receiving antiplatelet therapy, patients who were not receiving antiplatelet therapy at baseline were more likely to be younger, east Asian, and disabled, to have a haemorrhagic stroke or cardioembolic ischaemic stroke, and to have a history of hypertension or atrial fibrillation ([table 1](#tbl1){ref-type="table"}). They were less likely to be smokers and to have a history of peripheral vascular disease, hypercholesterolaemia, diabetes, ischaemic heart disease, and a revascularisation procedure. Of patients who were or were not receiving antiplatelet therapy at baseline, baseline characteristics were evenly distributed between patients assigned to receive either B vitamins or placebo ([table 2](#tbl2){ref-type="table"}).

Baseline antiplatelet therapy was an independent significant predictor of a lower rate of subsequent stroke, myocardial infarction, or death from vascular causes in all patients who entered randomisation (hazard ratio \[HR\] 0·66, 95% CI 0·55--0·81).

Of the 6609 participants in receipt of antiplatelet drugs at baseline, the primary outcome was recorded in roughly 15% of participants assigned to receive B vitamins or placebo ([table 3](#tbl3){ref-type="table"}). By contrast, of the 1463 participants who were not in receipt of antiplatelet drugs at baseline, the primary outcome was recorded in slightly more participants in the placebo group ([table 3](#tbl3){ref-type="table"}). After adjusting for the effects of imbalance in baseline variables, the HR for the primary outcome for patients assigned B vitamins versus placebo was greater for participants taking antiplatelet therapy than for those who were not ([table 3](#tbl3){ref-type="table"}).

The [figure](#fig1){ref-type="fig"} shows Kaplan-Meier curves of the cumulative probability of the primary outcome event in patients who were and were not taking antiplatelet at the time of randomisation into the VITATOPS trial. In [table 3](#tbl3){ref-type="table"} we also show the results for the individual components of the primary outcome. The overall results for the primary outcome were consistent for stroke and for vascular death, but not for myocardial infarction.

In [table 4](#tbl4){ref-type="table"} we show a significant interaction between antiplatelet use at baseline and the effect of B vitamins on recurrent ischaemic stroke after adjustment for baseline factors. The trend was similar, but not significant, for recurrent haemorrhagic stroke.

In [table 5](#tbl5){ref-type="table"} we show that of all the listed subgroups, with the exception of participants with cardioembolic ischaemic stroke, the HR for the effect of B vitamins compared with placebo on the primary outcome was lower in patients who were not in receipt of antiplatelet therapy at baseline than in patients who were, but many of the comparisons were not statistically significant.

In [table 6](#tbl6){ref-type="table"} we show that supplementation with B vitamins significantly lowered total homocysteine and increased red cell folate concentration during follow-up in patients who were and were not in receipt of antiplatelet therapy at baseline. Supplementation with B vitamins also significantly increased serum vitamin B~12~ concentration during follow-up in patients in receipt of antiplatelet therapy at baseline, but the effect was not significant for patients not receiving antiplatelet therapy at baseline. The effects of supplementation with B vitamins on lowering total homocysteine and increasing red-cell folate and vitamin B~12~ concentration were not significantly different between patients who were and were not in receipt of antiplatelet therapy at baseline. The p for interaction between antiplatelet therapy at baseline and trial treatment was 0·2501 for total homocysteine, 0·8996 for red cell folate, and 0·6591 for vitamin B~12~.

After excluding patients with a qualifying diagnosis of haemorrhagic stroke, the interaction between B vitamins and antiplatelet therapy was not significant (adjusted p=0·1159), but the adjusted HR for B vitamins versus placebo on the primary outcome in participants not in receipt of antiplatelet therapy at baseline was still lower (HR 0·75, 95% CI 0·54--1·03) than in participants who were in receipt of therapy (0·98, 0·86--1·12). We also did a matched paired analysis, and a similar pattern was evident.

Discussion {#cesec80}
==========

The principal result of the VITATOPS trial was that daily administration of B vitamins to patients with recent stroke or transient ischaemic attack for a median of 3·4 years had no significant effect, compared with placebo, on the overall incidence of major vascular events. However, our post-hoc subanalysis supports hypotheses from previous independent trials of lowering total homocysteine on both ischaemic heart disease and stroke outcome events that antiplatelet therapy, which was taken by most patients, might have modified any favourable effect of folic acid supplementation on major vascular events ([panel](#box1){ref-type="boxed-text"}).[@bib7; @bib9]

The VITATOPS trial had several strengths: systematic bias in treatment allocation was minimised by the randomisation process; observer bias in the assessment of vascular outcomes was minimised by the masking of treatment allocation from assessors, clinicians, and patients; and random error was reduced by the reasonably large number of outcome events. The strengths of our analysis are that it was based on a pre-existing hypothesis (that antiplatelet therapy might interact with the effect of B vitamins on vascular risk), the hypothesis is plausible, the interaction between B-vitamin supplementation and only one subgroup was assessed (antiplatelet use at baseline or not; [table 3](#tbl3){ref-type="table"}), the primary trial outcome was the main outcome studied, the distribution of important prognostic factors was reasonably, although not perfectly, balanced between treatment groups within each subgroup ([table 2](#tbl2){ref-type="table"}), the analysis was based on appropriate statistical tests of subgroup-treatment effect interaction, all subgroup analyses that were undertaken have been reported, and the results have been interpreted cautiously on the premise that subgroup analyses are intrinsically limited.[@bib15]

Potential limitations are that, because this substudy was not a primary aim or prespecified analysis of the VITATOPS trial, the type of antiplatelet therapy taken (eg, aspirin, clopidogrel, aspirin combined with dipyridamole) was not recorded, and there was a significant imbalance in baseline characteristics of participants in receipt of antiplatelet therapy compared with participants who were not ([table 1](#tbl1){ref-type="table"}), and a mild imbalance in baseline characteristics in participants assigned to receive B vitamins versus placebo ([table 2](#tbl2){ref-type="table"}). The more favourable recorded effect of B vitamins in participants not in receipt of antiplatelet therapy might have been confounded by the reason they were not in receipt of the therapy---ie, B vitamins might have been more effective in patients of east Asian origin or patients with cardioembolic ischaemic stroke or intracerebral haemorrhage (who tend not be given antiplatelet drugs). However, we adjusted for the effects of this imbalance on the rates of each vascular outcome in our Cox multiple regression analysis. Through our Cox analysis we identified that, after adjusting for these effects, the use of antiplatelet therapy at baseline was a significant, independent predictor of the incidence of major vascular events (p\<0·0001) and that there was a significant interaction between antiplatelet therapy and treatment with B vitamins on the primary outcome (adjusted p for interaction=0·0204), stroke (adjusted p for interaction=0·0134), and death from vascular causes (adjusted p for interaction=0·0225). We acknowledge the possibility of residual imbalance in other, unmeasured, prognostic factors at baseline, for which we could not adjust our analysis, and that such residual confounding after adjusting for imbalances in measured prognostic factors (eg, haemorrhagic stroke, cardioembolic ischaemic stroke) could affect our results. We also acknowledge that our findings might represent not an interaction of B-vitamin supplementation with antiplatelet therapy but a significant effect of lowering homocysteine by B-vitamin supplementation in patients with haemorrhagic stroke or cardioembolic ischaemic stroke.

If our findings are valid, the mechanisms by which raised homocysteine might impair vascular function in the absence of antiplatelet therapy remain to be ascertained. Laboratory investigations suggest several potential mechanisms, including impairment of endothelial function, oxidation of low-density lipids, increased monocyte adhesion to the blood vessel wall, increased lipid uptake and retention, activation of inflammatory pathways, stimulatory effects on smooth-muscle-cell proliferation, and prothrombotic tendency mediated by activation of coagulation factors and platelet dysfunction.[@bib11; @bib12; @bib13] If antiplatelet therapy really does modify the effects of lowering homocysteine on vascular outcomes, this might be mediated by direct effects of antiplatelet drugs on platelet activation and thrombus formation, or indirect effects of antiplatelet drugs, such as aspirin, in reducing vasoconstrictor tone, vascular smooth-muscle-cell proliferation, and release of inflammatory cytokines, oxygen radicals, and growth factors.[@bib10]

In conclusion, our findings of a significant interaction between antiplatelet therapy and the effect of B vitamins on the primary outcome, in our exploratory analysis of an independent group of patients with previous stroke or transient ischaemic attack, support the hypothesis generated from other studies that antiplatelet therapy might modify any potential benefits of lowering homocysteine with folic-acid supplementation in the secondary prevention of major vascular events. Rather than antiplatelet therapy negating all of the effects of lowering homocysteine, it is also possible that lowering homocysteine might have a small benefit independent of antiplatelet therapy and a larger benefit in the absence of additional prophylactic antiplatelet therapy.

The external validity of our findings can be assessed more reliably by means of a meta-analysis of the relevant data from all individual patients enrolled in trials of B vitamins to prevent both stroke and ischaemic heart disease events. If validated, the implications of the findings for clinicians are that B vitamins might have a role in the prevention of vascular events in individuals at high risk but who have an allergy to, intolerance of, or lack of indication for antiplatelet therapy, such as those who are also at risk of bleeding events (eg, haemorrhagic stroke).
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======================
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![Kaplan-Meier curves of the cumulative probability of the primary outcome event\
Cumulative probability of stroke, myocardial infarction, or death from vascular causes in patients with previous stroke or transient ischaemic attack who were (A) or were not (B) in receipt of antiplatelet therapy at the time of randomisation into the VITATOPS trial.](gr1){#fig1}

###### 

Baseline characteristics

                                                                                                                                                   **Antiplatelet treatment (N=6609)**   **No antiplatelet treatment (N=1463)**   **p value**
  ---------------------------------------------- ----------------------------------------------------------- ------------------------------------- ------------------------------------- ---------------------------------------- -------------
  Age (years)                                    62·9 (12·3)                                                 61·1 (13·2)                           \<0·0001                                                                       
  Men                                            4227 (64·0%)                                                922 (63·0%)                           0·4910                                                                         
  Women                                          2380 (36·0%)                                                541 (37·0%)                           ..                                                                             
  Ethnic origin                                                                                                                                                                                                                   
                                                 White                                                       2755 (43·2%)                          511 (36·3%)                           \<0·0001                                 
                                                 East Asian                                                  1455 (22·8%)                          445 (31·6%)                           ..                                       
                                                 South Asian                                                 1733 (27·2%)                          316 (22·4%)                           ..                                       
                                                 Other                                                       435 (6·8%)                            136 (9·7%)                            ..                                       
  Oxfordshire classification of stroke subtype                                                                                                                                                                                    
                                                 Total anterior circulation syndrome                         132 (2·0%)                            60 (4·1%)                             \<0·0001                                 
                                                 Partial anterior circulation syndrome                       3512 (53·7%)                          780 (53·9%)                           ..                                       
                                                 Lacunar syndrome                                            2516 (38·5%)                          511 (35·3%)                           ..                                       
                                                 Posterior circulation syndrome                              382 (5·8%)                            95 (6·6%)                             ..                                       
  Pathological subtype of stroke                                                                                                                                                                                                  
                                                 Transient ischaemic attack                                  1250 (18·9%)                          146 (10·0%)                           \<0·0001                                 
                                                 Ischaemic stroke                                            5117 (77·5%)                          574 (39·3%)                           ..                                       
                                                 Intracerebral haemorrhage                                   82 (1·2%)                             654 (44·8%)                           ..                                       
                                                 Subarachnoid haemorrhage                                    10 (0·2%)                             56 (3·8%)                             ..                                       
                                                 Retinal infarction                                          16 (0·2%)                             2 (0·1%)                              ..                                       
                                                 Unknown or uncertain pathology                              126 (1·9%)                            29 (2·0%)                             ..                                       
  Causal subtype of stroke                                                                                                                                                                                                        
                                                 Large artery disease                                        2788 (42·5%)                          227 (15·6%)                           \<0·0001                                 
                                                 Small artery disease                                        2555 (38·9%)                          203 (14·0%)                           ..                                       
                                                 Embolism from the heart                                     190 (2·9%)                            209 (14·4%)                           ..                                       
                                                 Uncertain or unknown                                        911 (13·9%)                           97 (6·7%)                             ..                                       
                                                 Haemorrhagic event                                          118 (1·8%)                            718 (49·4%)                           ..                                       
  Oxford handicap score                                                                                                                                                                                                           
                                                 2 or less (independent)                                     5136 (79·0%)                          902 (63·2%)                           \<0·0001                                 
                                                 3 or greater (dependent)                                    1366 (21·0%)                          525 (36·8%)                           ..                                       
  Medical history                                                                                                                                                                                                                 
                                                 Stroke                                                      1041 (15·8%)                          233 (16·1%)                           0·7732                                   
                                                 Myocardial infarction                                       501 (7·6%)                            95 (6·6%)                             0·1797                                   
                                                 Peripheral arterial disease                                 321 (4·9%)                            44 (3·0%)                             0·0024                                   
                                                 Revascularisation procedure of brain, heart, or limbs       482 (7·3%)                            82 (5·6%)                             0·0219                                   
                                                 Hypertension[\*](#tbl1fn1){ref-type="table-fn"}             4634 (70·3%)                          1081 (74·7%)                          0·0009                                   
                                                                                                             Treated hypertension event            3631 (55·3%)                          783 (54·2%)                              0·4516
                                                 Smoking                                                     3337 (50·7%)                          671 (46·4%)                           0·0033                                   
                                                                                                             Present smoker or at time of event    1615 (24·6%)                          288 (19·9%)                              0·0001
                                                 Hypercholesterolaemia[†](#tbl1fn2){ref-type="table-fn"}     2315 (35·2%)                          330 (22·9%)                           \<0·0001                                 
                                                                                                             Treated hypercholesterolaemia event   2001 (30·6%)                          266 (18·6%)                              \<0·0001
                                                 Diabetes mellitus                                           1641 (24·9%)                          254 (17·5%)                           \<0·0001                                 
                                                 Atrial fibrillation                                         333 (5·1%)                            313 (21·6%)                           \<0·0001                                 
                                                 Ischaemic heart disease                                     1126 (17·6%)                          197 (14·1%)                           0·0014                                   
                                                 History of depression                                       451 (7·6%)                            92 (7·0%)                             0·4947                                   
                                                 Alcohol intake (standard drinks \[10 g alcohol\] per day)   0·8 (2·5)                             0·9 (2·5)                             0·1888                                   

Data are mean (SD) or n (%).

History of hypertension or treated hypertension at randomisation.

History of hypercholesterolaemia (\>6·5 mmol/L) or treated hypercholesterolaemia at randomisation.

###### 

Baseline characteristics by treatment allocation

                                                                                                                                                   **Antiplatelet treatment (N=6609)**   **No antiplatelet treatment (N=1463)**                 
  ---------------------------------------------- ----------------------------------------------------------- ------------------------------------- ------------------------------------- ---------------------------------------- ------------- -------------
  Age (years)                                    63·0 (12·2)                                                 62·8 (12·4)                           61·3 (13·0)                           61·0 (13·3)                                            
  Men                                            2097 (63·5%)                                                2130 (64·4%)                          475 (65·2%)                           447 (60·9%)                                            
  Women                                          1205 (36·5%)                                                1175 (35·6%)                          254 (34·8%)                           287 (39·1%)                                            
  Ethnic origin                                                                                                                                                                                                                                 
                                                 White                                                       1378 (43·3%)                          1377 (43·1%)                          257 (36·5%)                              254 (36·1%)   
                                                 East Asian                                                  732 (23·0%)                           723 (22·6%)                           217 (30·8%)                              228 (32·4%)   
                                                 South Asian                                                 857 (26·9%)                           876 (27·4%)                           159 (22·6%)                              157 (22·3%)   
                                                 Other                                                       215 (6·8%)                            220 (6·9%)                            71 (10·1%)                               65 (9·2%)     
  Oxfordshire classification of stroke subtype                                                                                                                                                                                                  
                                                 Total anterior circulation syndrome                         71 (2·2%)                             61 (1·9%)                             31 (4·3%)                                29 (4·0%)     
                                                 Partial anterior circulation syndrome                       1758 (53·8%)                          1754 (53·6%)                          390 (54·1%)                              390 (53·8%)   
                                                 Lacunar syndrome                                            1256 (38·4%)                          1260 (38·5%)                          253 (35·1%)                              258 (35·6%)   
                                                 Posterior circulation syndrome                              184 (5·6%)                            198 (6·0%)                            47 (6·5%)                                48 (6·6%)     
  Pathological subtype of stroke                                                                                                                                                                                                                
                                                 Transient ischaemic attack                                  634 (19·2%)                           616 (18·7%)                           80 (11·0%)                               66 (9·0%)     
                                                 Ischaemic stroke                                            2560 (77·6%)                          2557 (77·4%)                          278 (38·2%)                              296 (40·4%)   
                                                 Intracerebral haemorrhage                                   37 (1·1%)                             45 (1·4%)                             317 (43·5%)                              337 (46·0%)   
                                                 Subarachnoid haemorrhage                                    4 (0·1%)                              6 (0·2%)                              30 (4·1%)                                26 (3·5%)     
                                                 Retinal infarction                                          9 (0·3%)                              7 (0·2%)                              2 (0·3%)                                 0 (0%)        
                                                 Unknown or uncertain pathology                              55 (1·7%)                             71 (2·2%)                             21 (2·9%)                                8 (1·1%)      
  Causal subtype of stroke                                                                                                                                                                                                                      
                                                 Large artery disease                                        1405 (42·9%)                          1383 (42·1%)                          118 (16·3%)                              109 (15·0%)   
                                                 Small artery disease                                        1281 (39·1%)                          1274 (38·8%)                          104 (14·3%)                              99 (13·6%)    
                                                 Embolism from the heart                                     88 (2·7%)                             102 (3·1%)                            97 (13·4%)                               112 (15·4%)   
                                                 Uncertain or unknown                                        453 (13·8%)                           458 (13·9%)                           54 (7·4%)                                43 (5·9%)     
                                                 Haemorrhagic event                                          50 (1·5%)                             68 (2·1%)                             353 (48·6%)                              365 (50·1%)   
  Oxford handicap score                                                                                                                                                                                                                         
                                                 2 or less (independent)                                     2556 (78·7%)                          2580 (79·2%)                          461 (64·8%)                              441 (61·6%)   
                                                 3 or greater (dependent)                                    690 (21·3%)                           676 (20·8%)                           250 (35·2%)                              275 (38·4%)   
  Medical history                                                                                                                                                                                                                               
                                                 Stroke                                                      528 (16·0%)                           513 (15·6%)                           126 (17·5%)                              107 (14·8%)   
                                                 Myocardial infarction                                       255 (7·8%)                            246 (7·5%)                            45 (6·3%)                                50 (6·9%)     
                                                 Peripheral arterial disease                                 163 (5·0%)                            158 (4·8%)                            25 (3·5%)                                19 (2·6%)     
                                                 Revascularisation procedure of brain, heart, or limbs       248 (7·5%)                            234 (7·1%)                            44 (6·0%)                                38 (5·2%)     
                                                 Hypertension[\*](#tbl2fn1){ref-type="table-fn"}             2330 (70·7%)                          2304 (69·9%)                          534 (74·0%)                              547 (75·4%)   
                                                                                                             Treated hypertension event            1812 (55·2%)                          1819 (55·4%)                             390 (54·2%)   393 (54·2%)
                                                 Smoking                                                     1669 (50·7%)                          1668 (50·6%)                          332 (45·9%)                              339 (46·9%)   
                                                                                                             Present smoker or at time of event    806 (24·6%)                           809 (24·6%)                              138 (19·1%)   150 (20·7%)
                                                 Hypercholesterolaemia[†](#tbl2fn2){ref-type="table-fn"}     1157 (35·1%)                          1158 (35·2%)                          161 (22·4%)                              169 (23·4%)   
                                                                                                             Treated hypercholesterolaemia event   987 (30·2%)                           1014 (31·0%)                             135 (19·0%)   131 (18·2%)
                                                 Diabetes mellitus                                           823 (25·0%)                           818 (24·8%)                           121 (16·7%)                              133 (18·3%)   
                                                 Atrial fibrillation                                         165 (5·0%)                            168 (5·1%)                            152 (21·1%)                              161 (22·2%)   
                                                 Ischaemic heart disease                                     573 (18·0%)                           553 (17·3%)                           96 (13·7%)                               101 (14·5%)   
                                                 History of depression                                       218 (7·3%)                            233 (7·8%)                            52 (8·0%)                                40 (6·1%)     
                                                 Alcohol intake (standard drinks \[10 g alcohol\] per day)   0·9 (2·7)                             0·8 (2·2)                             0·8 (2·2)                                1·0 (2·8)     

Data are mean (SD) or n (%).

History of hypertension or treated hypertension at randomisation.

History of hypercholesterolaemia (\>6·5 mmol/L) or treated hypercholesterolaemia at randomisation.

###### 

Interaction between B-vitamin supplementation and antiplatelet therapy at baseline on each major vascular outcome

                                                         **B-vitamins group**   **Placebo group**   **Hazard ratio (95% CI)**   **p for interaction**   **Adjusted hazard ratio (95% CI)**[\*](#tbl3fn1){ref-type="table-fn"}   **Adjusted p for interaction**[\*](#tbl3fn1){ref-type="table-fn"}                       
  ------------------------------------------------------ ---------------------- ------------------- --------------------------- ----------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------- ------------------- --------
  **Stroke, myocardial infarction, or vascular death**                                                                                                                                                                                                                                                                  
  Antiplatelet use                                       3306                   488 (14·8%)         3303                        519 (15·7%)             0·94 (0·83--1·07)                                                       0·0980                                                              0·98 (0·86--1·11)   0·0204
  No antiplatelet use                                    734                    123 (16·8%)         729                         153 (21·0%)             0·76 (0·60--0·96)                                                                                                                           0·71 (0·55--0·90)   
  **Stroke**                                                                                                                                                                                                                                                                                                            
  Antiplatelet use                                       3306                   293 (8·9%)          3303                        297 (9·0%)              0·99 (0·84--1·17)                                                       0·0452                                                              1·03 (0·87--1·22)   0·0134
  No antiplatelet use                                    734                    65 (8·9%)           729                         89 (12·2%)              0·69 (0·50--0·95)                                                                                                                           0·65 (0·46--0·91)   
  **Vascular death**                                                                                                                                                                                                                                                                                                    
  Antiplatelet use                                       3306                   254 (7·7%)          3303                        278 (8·4%)              0·92 (0·78--1·10)                                                       0·0838                                                              0·96 (0·81--1·16)   0·0225
  No antiplatelet use                                    734                    70 (9·5%)           729                         97 (13·3%)              0·68 (0·50--0·93)                                                                                                                           0·63 (0·46--0·88)   
  **Myocardial infarction**                                                                                                                                                                                                                                                                                             
  Antiplatelet use                                       3306                   98 (3·0%)           3303                        95 (2·9%)               1·04 (0·78--1·37)                                                       0·6630                                                              0·97 (0·72--1·31)   0·9588
  No antiplatelet use                                    734                    18 (2·5%)           729                         19 (2·6%)               0·90 (0·47--1·72)                                                                                                                           0·89 (0·45--1·79)   
  **Stroke or vascular death**                                                                                                                                                                                                                                                                                          
  Antiplatelet use                                       3306                   453 (13·7%)         3303                        476 (14·4%)             0·96 (0·84--1·09)                                                       0·0553                                                              0·99 (0·87--1·14)   0·0072
  No antiplatelet use                                    734                    113 (15·4%)         729                         145 (19·9%)             0·74 (0·57--0·94)                                                                                                                           0·68 (0·52--0·88)   

Adjusted for age, sex, ethnic origin, history of stroke, myocardial infarction, hypertension, ischaemic heart disease, peripheral arterial disease, diabetes, cholesterol, smoking status, Oxford handicap score, pathology, and cause of stroke and transient ischaemic attack.

###### 

Interaction between B-vitamin supplementation and antiplatelet therapy at baseline on recurrent stroke subtypes

                                                                                                                                         **B-vitamins group**   **Placebo group**   **Hazard ratio (95% CI)**   **p for interaction**   **Adjusted hazard ratio (95% CI)**[\*](#tbl4fn1){ref-type="table-fn"}   **Adjusted p for interaction**[\*](#tbl4fn1){ref-type="table-fn"}                        
  ---------------------------------------------------------------------------------------------------------------- --------------------- ---------------------- ------------------- --------------------------- ----------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------- -------------------- --------
  **All patients**[†](#tbl4fn2){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                     
  Recurrent stroke (ischaemic; first ever or recurrent)                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                   Antiplatelet use      3306                   212 (6·4%)          3303                        187 (5·7%)              1·14 (0·94--1·39)                                                       0·1154                                                              1·16 (0·94--1·43)    0·0392
                                                                                                                   No antiplatelet use   734                    36 (4·9%)           729                         44 (6·0%)               0·78 (0·50--1·21)                                                                                                                           0·69 (0·44--1·11)    
  Recurrent stroke (haemorrhagic; first ever or recurrent)                                                                                                                                                                                                                                                                                                                                               
                                                                                                                   Antiplatelet use      3306                   26 (0·8%)           3303                        24 (0·7%)               1·09 (0·63--1·90)                                                       0·0866                                                              1·10 (0·61--1·97)    0·0757
                                                                                                                   No antiplatelet use   734                    15 (2·0%)           729                         27 (3·7%)               0·52 (0·28--0·99)                                                                                                                           0·48 (0·24--0·94)    
  **Patients with only non-haemorrhagic stroke or transient ischaemic attack**[‡](#tbl4fn3){ref-type="table-fn"}                                                                                                                                                                                                                                                                                         
  Recurrent stroke (ischaemic; first ever or recurrent)                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                   Antiplatelet use      3255                   211 (6·5%)          3262                        187 (5·7%)              1·14 (0·93--1·38)                                                       0·3208                                                              1·16 (0·94--1·43)    0·1193
                                                                                                                   No antiplatelet use   371                    29 (7·8%)           382                         33 (8·6%)               0·88 (0·53--1·44)                                                                                                                           0·75 (0·44--1·29)    
  Recurrent stroke (haemorrhagic; first ever or recurrent)                                                                                                                                                                                                                                                                                                                                               
                                                                                                                   Antiplatelet use      3255                   25 (0·7%)           3262                        24 (0·7%)               1·05 (0·60--1·84)                                                       0·5815                                                              1·06 (0·59--1·93)    0·6016
                                                                                                                   No antiplatelet use   371                    7 (1·9%)            382                         9 (2·4%)                0·76 (0·28--2·05)                                                                                                                           0·69 (0·233--2·04)   

Adjusted for age, sex, ethnic origin, history of stroke, myocardial infarction, hypertension, ischaemic heart disease, peripheral arterial disease, diabetes, cholesterol, smoking status, Oxford handicap score, pathology, and cause of stroke and transient ischaemic attack.

Qualifying event was ischaemic or haemorrhagic stroke or transient ischaemic attack.

Qualifying event was only ischaemic stroke or transient ischaemic attack.

###### 

Interaction between B-vitamin supplementation and antiplatelet therapy at baseline on the primary outcome stratified by baseline characteristics

                                                              **B-vitamins group**   **Placebo group**   **Hazard ratio (95% CI)**   **p for interaction**   **Adjusted p for interaction**[\*](#tbl5fn1){ref-type="table-fn"}            
  ----------------------------------------------------------- ---------------------- ------------------- --------------------------- ----------------------- ------------------------------------------------------------------- -------- --------
  **Age \<60 years**                                                                                                                                                                                                                      
  Antiplatelet use                                            1237                   122 (9·9%)          1208                        135 (11·2%)             0·89 (0·70--1·13)                                                   0·4957   0·3521
  No antiplatelet use                                         325                    34 (10·5%)          319                         43 (13·5%)              0·75 (0·48--1·17)                                                            
  **Age between 60--69 years**                                                                                                                                                                                                            
  Antiplatelet use                                            960                    123 (12·8%)         995                         139 (14·0%)             0·90 (0·72--1·17)                                                   0·6991   0·4442
  No antiplatelet use                                         206                    43 (16·5%)          200                         38 (19·0%)              0·83 (0·52--1·32)                                                            
  **Age \>69 years**                                                                                                                                                                                                                      
  Antiplatelet use                                            1109                   243 (21·9%)         1100                        245 (22·3%)             1·00 (0·84--1·20)                                                   0·1018   0·0379
  No antiplatelet use                                         203                    55 (27·1%)          210                         72 (34·3%)              0·73 (0·51--1·03)                                                            
  **Transient ischaemic attack**                                                                                                                                                                                                          
  Antiplatelet use                                            616                    63 (10·2%)          634                         83 (13·1%)              0·79 (0·57--1·09)                                                   0·2669   0·3513
  No antiplatelet use                                         66                     6 (9·1%)            80                          17 (21·3%)              0·48 (0·19--1·22)                                                            
  **Ischaemic stroke**                                                                                                                                                                                                                    
  Antiplatelet use                                            2557                   405 (15·8%)         2560                        416 (16·3%)             0·98 (0·85--1·12)                                                   0·5673   0·2114
  No antiplatelet use                                         296                    75 (25·3%)          278                         73 (26·3%)              0·90 (0·65--1·24)                                                            
  **Non-haemorrhagic stroke or transient ischaemic attack**                                                                                                                                                                               
  Antiplatelet use                                            3255                   481 (14·8%)         3262                        512 (15·7%)             0·94 (0·83--1·07)                                                   0·5907   0·1159
  No antiplatelet use                                         371                    82 (22·10%)         382                         93 (24·4%)              0·87 (0·65--1·17)                                                            
  **Intracerebral haemorrhage**                                                                                                                                                                                                           
  Antiplatelet use                                            45                     6 (13·3%)           37                          7 (18·9%)               0·72 (0·24--2·14)                                                   0·5842   0·8060
  No antiplatelet use                                         337                    39 (11·6%)          317                         57 (18·0%)              0·58 (0·39--0·88)                                                            
  **Subarachnoid haemorrhage**                                                                                                                                                                                                            
  Antiplatelet use                                            6                      1 (16·7%)           4                           0 (0·0%)                ..                                                                  ..       ..
  No antiplatelet use                                         26                     2 (7·7%)            30                          3 (10·0%)               0·80 (0·13--4·80)                                                            
  **Large artery disease**                                                                                                                                                                                                                
  Antiplatelet use                                            1383                   255 (18·4%)         1405                        232 (16·5%)             1·13 (0·95--1·35)                                                   0·2104   0·0438
  No antiplatelet use                                         109                    24 (22·0%)          118                         31 (26·3%)              0·81 (0·47--1·37)                                                            
  **Small artery disease**                                                                                                                                                                                                                
  Antiplatelet use                                            1274                   167 (13·1%)         1281                        206 (16·1%)             0·80 (0·65--0·98)                                                   0·5589   0·8683
  No antiplatelet use                                         99                     23 (23·3%)          104                         33 (31·7%)              0·67 (0·39--1·14)                                                            
  **Embolism from the heart**                                                                                                                                                                                                             
  Antiplatelet use                                            102                    22 (21·6%)          88                          27 (30·7%)              0·64 (0·37--1·13)                                                   0·1576   0·8186
  No antiplatelet use                                         112                    27 (24·1%)          97                          21 (21·7%)              1·14 (0·64--2·01)                                                            
  **Smoking**                                                                                                                                                                                                                             
  Antiplatelet use                                            1668                   279 (16·7%)         1669                        275 (16·5%)             1·03 (0·87--1·22)                                                   0·0633   0·0553
  No antiplatelet use                                         339                    61 (18·0%)          332                         81 (24·4%)              0·73 (0·52--1·02)                                                            
  **No smoking**                                                                                                                                                                                                                          
  Antiplatelet use                                            1626                   206 (12·7%)         1623                        242 (14·9%)             0·84 (0·70--1·01)                                                   0·7663   0·1333
  No antiplatelet use                                         384                    61 (15·9%)          391                         71 (18·2%)              0·80 (0·57--1·13)                                                            
  **Diabetes**                                                                                                                                                                                                                            
  Antiplatelet use                                            818                    147 (18·0%)         823                         153 (18·6%)             1·00 (0·79--1·25)                                                   0·0555   0·0205
  No antiplatelet use                                         133                    32 (24·1%)          121                         43 (35·5%)              0·61 (0·39--0·97)                                                            
  **No diabetes**                                                                                                                                                                                                                         
  Antiplatelet use                                            2480                   339 (13·7%)         2471                        364 (14·7%)             0·93 (0·80--1·08)                                                   0·3179   0·1520
  No antiplatelet use                                         593                    89 (15·0%)          602                         109 (18·1%)             0·80 (0·60--1·06)                                                            
  **High cholesterol (≥6·5 mmol/L)**                                                                                                                                                                                                      
  Antiplatelet use                                            1158                   170 (14·7%)         1157                        184 (15·9%)             0·92 (0·75--1·14)                                                   0·3346   0·2473
  No antiplatelet use                                         169                    29 (17·2%)          161                         36 (22·4%)              0·72 (0·44--1·18)                                                            
  **Normal cholesterol (\<6·5 mmol/L)**                                                                                                                                                                                                   
  Antiplatelet use                                            1496                   214 (14·3%)         1463                        209 (14·3%)             1·03 (0·85--1·25)                                                   0·0265   0·0069
  No antiplatelet use                                         354                    51 (14·4%)          377                         75 (19·9%)              0·66 (0·46--0·94)                                                            
  **Treated high cholesterol**                                                                                                                                                                                                            
  Antiplatelet use                                            1014                   144 (14·2%)         987                         160 (16·2%)             0·88 (0·70--1·10)                                                   0·1825   0·2762
  No antiplatelet use                                         131                    22 (16·8%)          135                         25 (25·2%)              0·60 (0·35--1·03)                                                            
  **Untreated high cholesterol**                                                                                                                                                                                                          
  Antiplatelet use                                            2261                   339 (15·0%)         2283                        356 (15·6%)             0·97 (0·84--1·13)                                                   0·2154   0·0234
  No antiplatelet use                                         589                    97 (16·5%)          577                         114 (19·8%)             0·81 (0·62--1·07)                                                            

Adjusted for age, sex, ethnic origin, history of stroke, myocardial infarction, hypertension, ischaemic heart disease, peripheral arterial disease, diabetes, cholesterol, smoking status, Oxford handicap score, pathology, and cause of stroke and transient ischaemic attack.

###### 

Homocysteine, red cell folate, and vitamin B~12~ concentrations at baseline and during follow-up

                                 **Antiplatelet treatment**   **No antiplatelet treatment**                                                                           
  ------------------------------ ---------------------------- ------------------------------- -------------------------------------- --------------- ---------------- --------------------------------------
  **Homocysteine (μmol/L)**                                                                                                                                           
  B-vitamins group               13·7 (6·6)                   10·5 (4·4)                      −3·18 (−2·66 to −3·70); p\<0·0001      12·4 (4·3)      9·9 (2·6)        −2·46 (−1·46 to −3·46); p\<0·0001
  Placebo group                  13·4 (4·9)                   14·4 (5·8)                      0·94 (0·40 to 1·47); p=0·0006          13·3 (5·8)      13·8 (5·1)       0·56 (−0·50 to 1·63); p=0·2937
  **Red cell folate (nmol/L)**                                                                                                                                        
  B-vitamins group               971·6 (464·6)                2297·9 (789·4)                  1326·2 (1195·8 to 1456·6); p\<0·0001   906·8 (432·7)   2090·9 (752·3)   1184·1 (951·1 to 1417·2); p\<0·0001
  Placebo group                  867·0 (445·3)                1156·5 (686·0)                  289·5 (186·9 to 392·1); p\<0·0001      990·7 (515·9)   1112·9 (628·7)   122·2 (−109·2 to 353·5); p=0·2901
  **Vitamin B~12~ (pmol/L)**                                                                                                                                          
  B-vitamins group               312·3 (139·3)                367·5 (195·6)                   55·1 (21·3 to 89·0); p=0·0016          368·6 (192·4)   396·9 (239·4)    28·4 (−67·0 to 123·7); p=0·5494
  Placebo group                  311·9 (127·5)                205·7 (132·2)                   −106·2 (−79·7 to −132·8); p\<0·0001    342·7 (127·5)   186·4 (90·7)     −156·3 (−109·8 to −202·8); p\<0·0001

Data are mean (SD) unless otherwise stated.

Comparison between baseline and during the follow-up was undertaken with a paired *t* test. Some of the follow-up measures were taken during follow-up (eg, at the regular follow-up assessments every 6 months) and some at the end of follow-up.

###### Research in context

**Systematic review**

We searched PubMed with the terms "homocysteine", "folic acid", "vitamins", "antiplatelet", "aspirin", "clopidogrel", "dipyridamole", "cilostazol", "stroke", "ischaemic heart disease", "major vascular events", "interaction", "randomised trial", and "clinical trial" for reports of an interaction between antiplatelet therapy and treatments that lower homocysteine in the prevention of stroke and other major vascular events. We searched for work published before March, 2012. The quality of evidence we required was a randomised, controlled trial or meta-analysis of such trials. We identified the Heart Outcomes Prevention Evaluation 2 trial[@bib9] and the meta-analysis of randomised trials of lowering total homocysteine on risk of ischaemic heart disease events[@bib7] as directly relevant, and a further meta-analysis[@bib8] as indirectly relevant.

**Interpretation**

The results of our exploratory analyses of the VITATOPS trial support previous hypotheses that antiplatelet therapy, which was taken by most patients, might modify any favourable effect of folic acid supplementation on major vascular events.[@bib7; @bib9] If our finding are validated in independent studies, B vitamins might have a role in the prevention of vascular events in high-risk individuals with an allergy, intolerance, or lack of indication for antiplatelet therapy, such as those with haemorrhagic stroke.

[^1]: Members listed in the [appendix](#sec1){ref-type="sec"}
